We've got news for you.

Register on DispatchLIVE at no cost to receive newsletters, read exclusive articles & more.
Register now

Plan to seek emergency use nod for Covid-19 antibody therapy

Evidence has emerged of "profound efficacy" of the therapy. Stock photo.
Evidence has emerged of "profound efficacy" of the therapy. Stock photo.

Vir Biotechnology and Britain's GSK said on Wednesday they planned to seek emergency use authorisation (EUA) for their experimental Covid-19 antibody therapy after interim data from a study showed 85% reduction in hospitalisation and deaths among patients.

An independent panel recommended stopping further enrolment for the late-stage trial due to evidence of “profound efficacy” of the therapy, Vir and GSK said in a joint statement.

Antibody treatments are designed to decrease the severity of Covid-19 among patients diagnosed with the infection.

Additionally, the companies said a new laboratory study showed the therapy, VIR-7831, was equally effective against the UK, SA and Brazilian variants of the coronavirus.

Vir and GSK announced a partnership last year to research Covid-19 treatments.


Would you like to comment on this article or view other readers' comments? Register (it’s quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.